Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.41 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757777 | 1.00 | CA1 (0.46) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL6757780 | 1.00 | CA1 (0.46) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL15369721 | 1.00 | CA1 (0.46) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL15369688 | 1.00 | CA1 (0.46) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL6757782 | 1.00 | CA1 (0.46) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL6883399 | 0.84 | TRPA1 (0.37) | TRPA1TRPM8SHBG | |
| SCHEMBL6757991 | 0.84 | TRPA1 (0.37) | TRPA1TRPM8SHBG | |
| SCHEMBL6758029 | 0.84 | TRPA1 (0.37) | TRPA1TRPM8SHBG | |
| SCHEMBL10299083 | 0.83 | TRPA1 (0.40) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL1245044 | 0.83 | TRPA1 (0.45) | CA1CA2CA4TRPA1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079913-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140378680-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-25 | — | — | US | disclosed |
| US-8877796-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-04 | — | — | US | disclosed |
| US-8680132-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130296303-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-11-07 | — | — | US | disclosed |
| US-20120289494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | SANOFI (FR) | 2012-11-15 | — | — | US | disclosed |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378680-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | CA1 2973/4885CA2 3601/4885CA4 3975/4885 |
| US-20120289494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | CA1 2973/4885CA2 3601/4885CA4 3975/4885 |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | CA1 2973/4885CA2 3601/4885CA4 3975/4885 |
| US-20130296303-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | CA1 2973/4885CA2 3601/4885CA4 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.